Selective small molecular inhibitors like Nutlin-3a or Palbociclib have been suggested for enriching, respectively, TP53- and RB1-mutated cancer cell-derived organoids at the expense of organoids derived from TP53 and RB1 wildtype cell-derived organoids. The gene discussed is TP53; the disease is cancer.